Mainz Biomed B.V. (MYNZ): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYNZ Stock Summary
- MYNZ's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.54 -- higher than only 4.96% of US-listed equities with positive expected earnings growth.
- MYNZ's went public 1.08 years ago, making it older than just 0.9% of listed US stocks we're tracking.
- With a price/sales ratio of 282.53, MAINZ BIOMED NV has a higher such ratio than 98.84% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to MAINZ BIOMED NV, a group of peers worth examining would be LFST, AREB, FAMI, KXIN, and SOPA.
- To dig deeper into the stock's financial statements, go to MYNZ's page on browse-edgar?action=getcompany&CIK=0001874252.
MYNZ Valuation Summary
- MYNZ's price/sales ratio is 299.5; this is 5890% higher than that of the median Healthcare stock.
- MYNZ's price/earnings ratio has moved up 194.3 over the prior 13 months.
Below are key valuation metrics over time for MYNZ.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MYNZ | 2022-12-02 | 299.5 | 5.0 | -5.0 | -4.0 |
| MYNZ | 2022-12-01 | 311.5 | 5.2 | -5.2 | -4.2 |
| MYNZ | 2022-11-30 | 317.5 | 5.3 | -5.3 | -4.3 |
| MYNZ | 2022-11-29 | 319.7 | 5.4 | -5.3 | -4.3 |
| MYNZ | 2022-11-28 | 325.7 | 5.5 | -5.4 | -4.4 |
| MYNZ | 2022-11-25 | 316.7 | 5.3 | -5.3 | -4.3 |
MYNZ Stock Price Chart Interactive Chart >
MYNZ Price/Volume Stats
| Current price | $7.80 | 52-week high | $30.00 |
| Prev. close | $8.27 | 52-week low | $6.06 |
| Day low | $7.57 | Volume | 31,700 |
| Day high | $8.49 | Avg. volume | 170,309 |
| 50-day MA | $7.45 | Dividend yield | N/A |
| 200-day MA | $10.39 | Market Cap | N/A |
Mainz Biomed B.V. (MYNZ) Company Bio
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MYNZ News From Around the Web
Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory StrategiesFormer Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leaderBERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs. In this role, Ms. Levin will be in char |
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceBERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable conferences in November and December 2022, Deutsches Eigenkapitalforum 2022 and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference. Deutsches Eigenkapit |
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlerteAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023Enhances ColoFuture’s demographic profile and expedites data read-out timelinePotential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, anno |
H.C. Wainwright Remains a Buy on Mainz Biomed B.V. (MYNZ)H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Mainz Biomed B.V. (MYNZ - Research Report) today and set a price target of $25.00. The company's shares opened today at $7.50.Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Veru, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -24.1% and a 26.16% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mainz Biomed B.V. with a $20.00 average price target, implying a 166.67% upside from current levels. |
Mainz Biomed Provides Third Quarter 2022 UpdateBERKELEY, Calif. and MAINZ, Germany, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer today provided an update on accomplishments during the third quarter which ended September 30, 2022. Key Highlights and Recent Developments Expanded European and international commercial franchise for ColoAlert, the Company’s highly efficacious and easy-to-use DNA-based detecti |
MYNZ Price Returns
| 1-mo | 10.80% |
| 3-mo | -10.24% |
| 6-mo | -28.90% |
| 1-year | -3.11% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.93% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...